Contact Us
Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2025
Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2025

By Form (Injectables, Oral, Transdermal Patches), By Drug Class (5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class), By Emetogenic Risk (Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)), By Distribution Channel (CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores), By Application (Gynecology, Urology, Gastrointestinal Surgery, Other Applications) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

• Chemotherapy-Induced Nausea and Vomiting (CINV) market size has reached to $2.92 billion in 2024

• Expected to grow to $4.19 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%

• Growth Driver: Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market

• Market Trend: Innovative Antiemetic Solution Aims To Improve CINV Patient Outcomes

North America was the largest region in 2024.

What Is Covered Under Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Chemotherapy-induced nausea and vomiting (CINV) is a condition that causes nausea and vomiting sensation, which can develop due to chemotherapy treatment. It is a prevalent side-effect affecting many cancer patients, affecting their quality of life and treatment results. CINV can be managed and treated through medications and lifestyle changes.

The main types of forms of chemotherapy-induced nausea and vomiting (CINV) are injectables, oral and transdermal patches. Injectables are chemicals that are injected into the body to have various effects. The various drug classes are 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids and others and various emetogenic risks are highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC) and low emetogenic chemotherapy (LEC). The various distribution channels are CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies and drug stores applied in gynecology, urology, gastrointestinal surgery and others.

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and growth rate 2025 to 2029: Graph

What Is The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size 2025 And Growth Rate?

The chemotherapy-induced nausea and vomiting (CINV) market size has grown strongly in recent years. It will grow from $2.92 billion in 2024 to $3.13 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.

What Is The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Forecast?

The chemotherapy-induced nausea and vomiting (CINV) market size is expected to see strong growth in the next few years. It will grow to $4.19 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.

The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of NK1 receptor antagonists and 5-HT3 inhibitors sourced from India and Israel, exacerbating treatment side effects and increasing antiemetic medication costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segmented?

1) By Form: Injectables, Oral, Transdermal Patches

2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class

3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

Subsegments:

1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

2) By Oral: Tablets, Capsules, Liquid Formulations

3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

What Is Driving The Chemotherapy-Induced Nausea and Vomiting (CINV) Market? Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market

The increasing prevalence of cancer is expected to propel the growth of chemotherapy-induced nausea and vomiting (CINV) market going forward. Cancer is when some cells in the body develop uncontrolled and spread to other body regions. As cancer cases continue to grow, there is a greater incentive to develop more effective and targeted anti-emetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on CINV management has LED to advancements in understanding its underlying mechanisms and developing novel therapies. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, in the United States, IT is anticipated to be 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer deaths (about 1,670 deaths per day) in 2023. Therefore, the increasing prevalence of cancer will drive the chemotherapy-induced nausea and vomiting (CINV) industry.

What Is Driving The Chemotherapy-Induced Nausea and Vomiting (CINV) Market? Favourable Regulatory Initiatives Boost Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV)

The increasing favourable regulatory initiatives are expected to propel the growth of the chemotherapy-induced nausea and vomiting (CINV) market going forward. Regulatory initiatives are actions taken by regulatory bodies to develop, implement, or enforce regulations. Regulatory initiatives can be used to improve the prevention and management of chemotherapy-induced nausea and vomiting (CINV) to develop and implement guidelines for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). For instance, in October 2024, according to the Food and Drug Administration, a US-based federal agency protecting public health, in 2023, CDER (Center for Drug Evaluation and Research, a division of the U.S. Food and Drug Administration) approved 55 novel drugs for chemotherapy-induced nausea and vomiting (CINV). Therefore, the increasing favorable regulatory initiatives are driving the growth of the chemotherapy-induced nausea and vomiting (CINV) industry.

Who Are The Major Players In The Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

What Are The Key Trends Of The Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market? Innovative Antiemetic Solution Aims To Improve CINV Patient Outcomes

Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are working on new product innovations, such as fixed intravenous antiemetic, to gain a competitive advantage. A fixed intravenous antiemetic refers to a predetermined dose of medication administered through an IV to prevent or treat nausea and vomiting, commonly used in chemotherapy or post-surgery settings. For instance, in January 2023, Glenmark Pharmaceuticals Limited, an India-based manufacturer of pharmaceuticals, generics, and over-the-counter (OTC) products, introduced AKYNZEO I.V. in India, the first fixed intravenous antiemetic combination designed to prevent chemotherapy-induced nausea and vomiting (CINV). The product combines netupitant and palonosetron, targeting both acute and delayed phases of nausea and vomiting. It offers single-dose convenience, improved complete response rates, and enhanced quality of life for cancer patients. Clinical studies show IT is particularly beneficial for highly emetogenic chemotherapy patients.

Need data on a specific region in this market?

What Are Latest Mergers And Acquisitions In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market? Cumberland Pharmaceuticals Expands Cinv Portfolio With Acquisition Of Sancuso From Kyowa Kirin Inc

In January 2022, Cumberland Pharmaceuticals Inc., a US-based specialty pharmaceutical company, acquired SANCUSO (granisetron transdermal patch) from Kyowa Kirin Inc. for $13.5 million. With this acquisition, Cumberland will obtain the U.S. rights to SANCUSO (chemotherapy-induced nausea and vomiting (CINV) drug and will take full commercial responsibility for the product, including its marketing, promotion, distribution, manufacturing and medical support operations. Kyowa Kirin Inc. is a US-based subsidiary of Kyowa Kirin Co. Ltd. (Japan), a specialty pharmaceutical that develops innovative medicines used to prevent CINV.

Regional Outlook For The Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

The chemotherapy-induced nausea and vomiting (CINV) market consists of revenues earned by entities by providing services such as pharmacologic therapy and nonpharmacologic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-induced nausea and vomiting (CINV) market also includes the sales of such as olanzapine, dexamethasone, cannabinoids, metoclopramide, promethazine and prochlorperazine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?

The chemotherapy-induced nausea and vomiting (cinv) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced nausea and vomiting (cinv) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $3.13 billion
Revenue Forecast In 2034 $4.19 billion
Growth Rate CAGR of 7.5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications Subsegments: 1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Characteristics

3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies

4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Growth Analysis And Strategic Analysis Framework

5.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Rate Analysis

5.4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Total Addressable Market (TAM)

6. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segmentation

6.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injectables

Oral

Transdermal Patches

6.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

5-HT3 Receptor Antagonists

Neurokinin-1 Receptor Antagonists

Corticosteroids

Cannabinoids

Other Drug Class

6.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Highly Emetogenic Chemotherapy (HEC)

Moderately Emetogenic Chemotherapy (MEC)

Low Emetogenic Chemotherapy (LEC)

6.4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

CINV Hospitals

Cancer Research Institute

Retail Pharmacies

Online Pharmacies

Drug Stores

6.5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Gynecology

Urology

Gastrointestinal Surgery

Other Applications

6.6. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Injectables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous (IV) Solutions

Intramuscular (IM) Injections

6.7. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tablets

Capsules

Liquid Formulations

6.8. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Transdermal Patches, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Fentanyl Patches

Scopolamine Patches

7. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Regional And Country Analysis

7.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market

8.1. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market

9.1. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

9.2. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market

10.1. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market

11.1. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

11.2. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

12.1. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

13.1. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market

14.1. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

14.2. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market

15.1. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

15.2. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market

16.1. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market

17.1. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market

18.1. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market

19.1. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market

20.1. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market

21.1. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

21.2. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

22.1. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market

23.1. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

23.2. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market

24.1. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

24.2. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market

25.1. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

25.2. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market

26.1. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

26.2. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market

27.1. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market

28.1. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

28.2. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market

29.1. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

29.2. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Landscape And Company Profiles

30.1. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Landscape

30.2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Other Major And Innovative Companies

31.1. AstraZeneca plc

31.2. GlaxoSmithKline plc

31.3. Baxter International Inc.

31.4. Teva Pharmaceuticals Industries Ltd.

31.5. Bausch Health Companies Inc.

31.6. Eisai Co. Ltd.

31.7. Jazz Pharmaceuticals plc

31.8. Ono Pharmaceutical Co. Ltd.

31.9. Dr. Reddy’s Laboratories Ltd.

31.10. Kyowa Kirin Inc.

31.11. Amneal Pharmaceuticals Inc.

31.12. Mundipharma International Limited

31.13. Insys Therapeutics Inc.

31.14. Lupin Limited

31.15. Helsinn Holding S.A.

32. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market

34. Recent Developments In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market

35. Chemotherapy-Induced Nausea and Vomiting (CINV) Market High Potential Countries, Segments and Strategies

35.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2029 - Countries Offering Most New Opportunities

35.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2029 - Segments Offering Most New Opportunities

35.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Injectables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Transdermal Patches, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Pfizer Inc. Financial Performance
  • Table 80: Roche Holding AG Financial Performance
  • Table 81: Merck & Co. Inc. Financial Performance
  • Table 82: AbbVie Inc. Financial Performance
  • Table 83: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Injectables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Transdermal Patches, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Pfizer Inc. Financial Performance
  • Figure 80: Roche Holding AG Financial Performance
  • Figure 81: Merck & Co. Inc. Financial Performance
  • Figure 82: AbbVie Inc. Financial Performance
  • Figure 83: Novartis AG Financial Performance

Frequently Asked Questions

Chemotherapy-induced nausea and vomiting (CINV) is a condition that causes nausea and vomiting sensation, which can develop due to chemotherapy treatment. It is a prevalent side-effect affecting many cancer patients, affecting their quality of life and treatment results. CINV can be managed and treated through medications and lifestyle changes. For further insights on this market, request a sample here

The market major growth driver - Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market. For further insights on this market, request a sample here

The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $2.92 billion in 2024 to $3.13 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy. The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to " $4.19 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care. For further insights on this market, request a sample here

The chemotherapy-induced nausea and vomiting (cinv)market covered in this report is segmented –
1) By Form: Injectables; Oral; Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores
5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications Subsegments:
1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections
2) By Oral: Tablets; Capsules; Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches For further insights on this market,
request a sample here

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. For further insights on this market, request a sample here.

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.. For further insights on this market, request a sample here.

Major trends in this market include Innovative Antiemetic Solution Aims To Improve CINV Patient Outcomes. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Back to top WhatsApp icon